| INTRODUCTION
Peripheral blood CD34+ stem cells (PBSCs) collected using apheresis machines are the most common type of haematopoietic stem cells (HSCs) used for transplantation in human medicine. 1 Autologous stem cell transplantation combined with high-dose chemotherapy is part of standard therapy in human patients with aggressive haematological malignancies, such as non-Hodgkin lymphoma and multiple myeloma. 2, 3 In previous studies in veterinary medicine, dogs with Bor T-cell lymphoma were treated with autologous peripheral HSC transplantation combined with high-dose chemotherapy and total body irradiation. 4, 5 The findings of these studies suggest that PBSC transplantation can cure a subpopulation of dogs with B-and T-cell lymphoma.
In general, the peripheral blood of various animals, such as humans, rhesus macaques and dogs, contains a small number of HSCs. 6, 7 In both human and veterinary medicine, granulocyte colonystimulating factor (G-CSF) is the most commonly used agent for facilitating PBSC mobilization. [4] [5] [6] However, 10% to 29% of human patients, such as the elderly, heavily pre-treated patients, or patients with significant myelophthisis, fail to obtain optimal PBSC yields (>2.0 × 10 6 CD34+ cells/kg) with G-CSF and high-dose chemotherapy mobilization regimen to proceed with autologous HSC transplantation. 8, 9 In addition, higher PBSC yields, such as >4 to 5 × 10 6 CD34
+ cells/kg has been associated with faster neutrophil and platelet
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recovery, reduced hospitalization, need for blood transfusions, and antibiotic therapy, [10] [11] [12] although eventual rate of successful marrow reconstruction is not affected as long as the minimum target CD34+ cells are transplanted. 2 Therefore, the determination of a mobilization protocol that can yield higher PBSC counts for transplantation is essential to make this treatment more feasible.
Plerixafor reversibly inhibits the binding of chemokine stromal cell-derived factor-1α (SDF-1α) to its cognate receptor CXC chemokine receptor 4 (CXCR4). 13 SDF-1α and CXCR4 are expressed on bone marrow stromal cells and HSCs, respectively. Plerixafor disrupts the binding of CXCR4 and SDF-1α; as a result, HSCs in the bone marrow mobilize into the bloodstream. This agent has been used in people undergoing autologous PBSC transplantation in whom inadequate apheresis yield had been anticipated (ie, known poor mobilizers, heavily pre-treated patients, and elderly patients). 2, 13 In general, plerixafor is used in combination with G-CSF. In current human clinical studies, the HSC mobilization regimen, comprising G-CSF plus low-dose plerixafor (0.24 mg/kg), has been found to be more efficient than G-CSF alone for PBSC mobilization. 14, 15 In these studies, patients were treated with G-CSF for 4 to 5 days and were given plerixafor several hours prior to the apheresis. A study using a canine transplantation model has shown that a single administration of high-dose plerixafor (4 mg/kg) without G-CSF results in a mobilization of PBSCs sufficient for transplantation. 6 To the best of our knowledge, no study has evaluated the effectiveness of a regime comprising G-CSF and low-dose plerixafor for mobilization of PBSCs.
The Spectra Optia apheresis system (TerumoBCT, Lakewood, CO) was introduced in 2014 to replace the COBE Spectra apheresis system, which had been the most popular apheresis machine for use in humans for several decades. The Spectra Optia apheresis system has an advanced automated interface management system that automatically detects and maintains buffy coat interface for PBSC collection. 16 Earlier version of the Spectra Optia only supported a mononuclear cell (MNC) collection procedure, which has a secondary collection chamber that separates the MNCs from platelets. Continuous mononuclear cell (CMNC) collection procedure can be used on the newer version of the Spectra Optia. In contrast to the MNC collection procedure, this procedure eliminates the secondary collection chamber and allows for the mononuclear cells to be continuously transferred from the buffy coat into the collection bag. 17 While the COBE Spectra machine is safe and efficient at collecting PBSCs from veterinary species, including dogs, 4, 5 there is no published study, to our knowledge, that has examined the safety and feasibility of using the Spectra Optia machine in dogs. Therefore, in this pilot study, we had two goals: the primary objective was to evaluate the feasibility and safety of the Spectra Optia apheresis system and the CMNC procedure in dogs; the secondary objective was to compare three mobilization regimens in healthy dog (G-CSF alone, high-dose plerixafor alone, G-CSF plus lowdose plerixafor combination), to determine which regime yielded the highest number of harvested PBSCs during collections were performed using Spectra Optia apheresis system and the CMNC protocol.
| MATERIALS AND METHODS

| Animals
Nine healthy laboratory beagles (one intact male and eight intact females) were used in this study. The dogs weighed 9.7 to 11.4 kg (mean, 10.3 kg) and were aged 12 to 19 months (mean, 14.3 months).
These dogs were divided into three groups according to the assigned mobilization protocol (plerixafor, rhG-CSF, and combination regimen).
Each dog underwent mobilization and apheresis once. All animal procedures used in this study were reviewed and approved by the Institutional Animal Care and Use Committee of our institute (approval number: 15-0102). Prior to the experiments, complete blood counts (CBCs) and serum chemistries of each dog were analysed to confirm all values were within our reference intervals using a Procyte (IDEXX Laboratories, Tokyo, Japan) and Dri-Chem 7000 V (Fujifilm, Tokyo, Japan) machine, respectively.
| Stem cell mobilization regime
PBSCs were mobilized to peripheral blood using one of the three regimens. In plerixafor group (Dogs A, B and C), the dogs were administered high-dose plerixafor (4 mg/kg SC) (Sigma-Aldrich, Tokyo, Japan) 5 hours before starting the apheresis. 5 In G-CSF group (Dogs D, E and F), the dogs were administered rhG-CSF (5 μg/kg SC q12h) (Chugai Pharmaceutical Co., Ltd., Tokyo, Japan) starting 5 days before apheresis according to the previously published study, 18 except that the time between the last dose of rhG-CSF and start of apheresis was 9 hours so that the timing of harvest would be around 12 hours after the last dose of rh-GCSF (5 μg/kg; in the previous study, the last dose was doubled and given 2 h before apheresis). In the combination group (Dogs G, H and I), the dogs were administered the same protocol as in the G-CSF group, and low-dose plerixafor (0.24 mg/kg SC) 15 was administered 4 hours after the last rhG-CSF injection. Apheresis was then performed 5 hours after plerixafor administration.
During the mobilization treatment with rhG-CSF, CBCs were performed once daily and the day of the apheresis. For plerixafor/G-CSF combination group and plerixafor alone group, CBCs were also performed 1, 2, 3 and 4 hours following plerixafor administration. PBSC analysis using flow cytometry was performed on days 2 and 4 after rhG-CSF administration and 2 and 4 hours following plerixafor administration.
| Apheresis procedure
For the apheresis procedure, all animals were anaesthetised with propofol (6.0 mg/kg) (DS Pharma Animal Health, Osaka, Japan) administered intravenously. Subsequently, the animals were intubated and maintained on a mixture of isoflurane (DS Pharma Animal Health) in
oxygen. An 18-gauge, 5.1-cm catheter was placed percutaneously in a jugular vein. This catheter served to obtain blood samples and as an apheresis line. In addition, a 20-gauge, 5.1-cm catheter was placed in the saphenous vein for return of the blood from the apheresis circuit to the animal.
All MNC collections were performed using the Spectra Optia apheresis system and the CMNC protocol in conjunction with the approved disposable set (TerumoBCT). The initial priming of the tubing kit used stored autologous whole blood. This blood (200 mL) was extracted 2 to 3 weeks before apheresis; it was stored in a sterile blood-collection bag containing an acid-citrate-dextrose formula A (ACD-A) (TerumoBCT) at 4 C until the day of apheresis. 19 The extracorporeal volume of the Spectra Optia's CMNC tubing circuit was 253 mL (typical) to 297 mL (maximum) 20 ; however, as there are reservoir space within the circuit (usually filled with air), typical volumes of the whole blood used in this study to prime the circuit were less than 200 mL. The target blood volume to be processed was three times the total blood volume (90 × 3 mL/kg). The ACD-A solution (Terumo, Tokyo, Japan) infusion rate was set at 1. For the machine to run the apheresis, patient parameters including the patient's height, gender, weight, total blood volume (TBV) and haematocrit, had to be input into the machine. All values except height (which was always input as 80 cm, the minimum value the software accepted) and TBV (which was calculated as 90 mL/kg) were measured immediately before the procedure and input into the machine.
| Animal monitoring during apheresis
During apheresis, animals were monitored every 5 minutes by continuous electrocardiogram, oxygen saturation through pulse oximetry, end-tidal carbon dioxide, indirect blood pressure measurement, and rectal temperature. Air-heating pads were used to maintain the body temperature of the dogs within the physiological range. In the event where the mean arterial blood pressure decreased below 60 mm Hg, a continuous rate infusion (CRI) of dopamine hydrochloride (Kyowa Hakko Kirin, Tokyo, Japan) at 3 to 7 μg/kg/min was used to increase the blood pressure. Blood samples were collected by peripheral venocentesis every 20 minutes during apheresis to assess CBCs, sodium, potassium, chlorine and plasma total calcium. To avoid anticoagulant induced hypocalcaemia, 0.85% calcium gluconate solution (Nichi-Iko, Toyama, Japan) was administered as a CRI throughout the apheresis procedure. The infusion rate varied from 8.5 to 42.5 mg Ca/kg/h, depending on the total calcium concentration measured. The apheresis procedures were terminated when blood volume three times the calculated TBV had been processed. Rinse-back procedure was not performed.
| Apheresis product (PBSC) analysis
A sample of the apheresis product was subjected to PBSC count using Table 1 shows the collection parameters in the three mobilization groups. There were no significant differences between the three groups in any apheresis parameter. The mean blood volume processed, ACD volume, collection length, product volume and ACD volume in product in all nine dogs were 2.8 AE 0.2 L, 255.8 AE 12.7 mL, 229.3 AE 11.0 minutes, 116.9 AE 29.6 mL, and 13.3 AE 3.9 mL, respectively.
(1 H), 2 (2 H) 3 (3H) and 4 (4 H) hours after plerixafor administration, after 1 (DAY 1), 2 (DAY 2), 3 (DAY 3) and 4 (DAY 4) days of G-CSF administration, pre-plerixafor administration (PP), and pre-apheresis (PA). A, Plerixafor alone group, B, G-CSF alone group and C, G-CSF + plerixafor combination group
| Apheresis product composition
The apheresis products in the three groups contained a variable PBSC count ( Figure 4A ). The total PBSC count in Dogs A, B and C (the plerixafor group) were 1.6, 1.6 and 0.7 × 10 6 cells/kg, respectively; in 
| DISCUSSION
This pilot study compared three PBSC mobilization protocols in healthy beagle dogs and described, for the first time, PBSC apheresis using the Spectra Optia apheresis system and the CMNC protocol.
We demonstrated that the Spectra Optia apheresis system, when primed appropriately, is a safe and feasible alternative to the COBE Spectra apheresis system. In addition, our results suggest that either G-CSF alone or a combination of G-CSF and low-dose plerixafor facilitates the collection of and ample number of CD34+ PBSCs for an autologous HSC transplantation. Also, we demonstrated that apheresis using the Spectra Optia CMNC protocol in dogs weighing <12 kg is safe and feasible as with conventional machines.
In the plerixafor group, all three dogs failed to obtain sufficient PBSC yields (ie, <2.0 × 10 6 PBSCs/kg). In a previous study, a single administration of high-dose plerixafor resulted in efficient mobilization of PBSC for HSC transplantation in dogs (median PBSC count contained in the apheresis product, 3.9 × 10 6 /kg). 6 Conversely, the elevation of peripheral blood WBC and HSC counts up to 4 hours after plerixafor administration in the previous study was comparable to that in the present study. Variations in apheresis parameters and/or the timing of the collection of cells may have contributed to the failure to obtain a sufficient number of PBSCs in our study. In a similar study using a rhesus macaque model, the apheresis procedures were initiated 3 to 6 hours after plerixafor administration. 7 In the canine transplantation model study, the number of circulating PBSCs peaked at 8 hours following plerixafor administration in three of four dogs. 6 Based on these animal model studies, we set the mobilization protocol
consisting of approximately a 4-h apheresis initiated 5 hours after plerixafor administration. In human medicine, plerixafor is recommended to be given 10 to 11 hours before apheresis. 22 It is suggested that the response time to plerixafor varies depending on the individual or species. By delaying the start of apheresis by 1 to 2 hours, it may have been possible to increase the number of PBSCs collected by apheresis. Furthermore, as the present study aimed at comparing the three mobilization regimens, apheresis parameters were standardized based on the characteristics described above. These apheresis parameters may also have played a major role in the outcome of PBSC collection by apheresis in this study. Therefore, further consideration will be needed in future studies.
The apheresis products contained >3.0 × 10 6 PBSCs/kg and > 4.0 × 10 6 PBSCs/kg in all three dogs of the G-CSF alone and G-CSF + low dose plerixafor combination protocol group, respectively. According to human and canine studies, the desired cell dose that would guarantee successful HSC transplantation is 2.0 × 10 6 PBSCs/kg, although engrafting with lower transplanted cell doses, such as 1.5× 10 6 PBSCs/kg has been reported in dogs. 4 This suggests that both G-CSF and the combination protocols provided sufficient mobilization, and adding plerixafor may not provide additional benefit; however, a higher number of infused PBSCs, such as >4 to 5 × 10 6 PBSCs/kg, is sometimes targeted for treatment in humans as it reportedly leads to earlier PLT and neutrophil recovery and better clinical outcome.
2,4,23
Non-Hodgkin's lymphoma data of human autologous PBSC transplantation suggest that with the G-CSF and plerixafor mobilization protocol, a significantly higher proportion of patients (59%) can achieve the target PBSC count (>5.0 × 10 6 PBSCs/kg) in fewer days of apheresis compared with that by G-CSF alone (20%). 15 In human tumour cases of poor mobilization in response to G-CSF alone, plerixafor may rescue patients from mobilization failure. In a previous study, 75%
(42/56 cases) of patients who had failed to achieve a minimal cell dose or did not proceed to apheresis owing to a low PBSC count with conventional mobilization protocol (without plerixafor) successfully FIGURE 4 Mean AE SD of peripheral blood stem cell (PBSC), white blood cell (WBC), lymphocyte (LYM), and monocyte (MONO) of the apheresis products in the three groups. PBSC A, counts were quantified by flow cytometry. WBC, LYM, and MONO B, were measured by haematology analyser. Abbreviation: NS, no statistical difference. *P < 0.05 reached the target PBSC count (>2.0 × 10 6 PBSCs/kg) after undergoing a G-CSF + plerixafor protocol. 24 To the best of our knowledge, this combination protocol has not been evaluated in terms of efficacy and feasibility of apheresis in experimental or clinical canine studies.
Although not statistically significant, a trend toward increased PBSCs in the apheresis product with G-CSF/plerixafor combination protocol was observed in this study compared with mobilization with G-CSF alone. Because PBSCT is a relatively uncommonly performed procedure in veterinary practice and there has not been a reported case of poor mobilizer in dogs, perhaps because of less intensive conditioning regimen than in people, the role of plerixafor in veterinary PBSCT is yet to be determined.
In the present study, peripheral PLT counts and haematocrit decreased after plerixafor administration in some dogs. In the rhesus macaque model study, subcutaneous injection of plerixafor resulted in a decrease in peripheral PLT counts. 7 Furthermore, plerixafor influences red blood cells and PLTs; it reportedly causes anaemia or thrombocytopenia in 3% to 6% of human patients. 13, 25 However, few studies on plerixafor mention on the severities of these adverse events or the occurrence of any other serious adverse events. In the present study, clinical symptoms related to thrombocytopenia or anaemia were not observed after plerixafor administration. Also acute diarrhoea, observed in people who received plerixafor, 15 were not noted in any of the six dogs that received low-or high-dose plerixafor;
therefore, it was shown that plerixafor and the mobilization protocols used in this study can be safely performed in dogs.
Overall, the mean PLT counts in peripheral blood pre-and postapheresis were 263 AE 43.2 and 134 AE 31.1 × 10 3 cells/μL, respectively. The mean PLT attrition rate associated with apheresis using the Spectra Optia CMNC protocol was 48% (33.5%-66.5%). Consistent with our results, previous human and canine apheresis studies described a decrease in PLT count (27.0%-44.7%) after apheresis compared with the count before apheresis. 16, [26] [27] [28] Loss of PLTs is an adverse effect commonly associated with apheresis. Punzel et al. evaluated the impact of a lower packing factor (PF) for the CMNC protocol on decreased product PLT yield. 26 Although the PF was set uniformly by 4.5 (machine default value) in the present study, it is possible to preserve PLTs if a lower PF, such as 4.0, is used.
In this study, eight of the nine dogs experienced mild anaemia before blood was collected to the apheresis machine. Although no abnormal haematological changes were identified on the day of apheresis in these dogs (data not shown), anaemia was confirmed after the induction of anaesthesia. This haematological change in all eight dogs was resolved, and haemoglobin values were within the normal range by 24 hours after apheresis. The cause of anaemia in these eight dogs was unclear. However, it is possible that the mobilization regimens and apheresis procedure were not the direct cause of this phenomenon. Apheresis in paediatric patients and dogs (ie, low-weight patients) has raised similar concerns regarding a larger machine and tubing kit priming volume (extracorporeal volume) compared with the patient's blood volume. 16 Therefore, in these low-weight patients, the apheresis machine was primed with saline, albumin solution, packed red blood cells, or whole blood. In a previous study, three dogs weighing <14.0 kg had mild-to-moderate anaemia (packed cell volume;
17%-35%) after apheresis. 29 In that study, a combination of colloid and crystalloid solutions, saline and autologous whole blood were used as priming solutions. In the present study, the machine priming was performed using stored autologous whole blood, which resulted in the maintenance of the haematocrit during apheresis. Thus, this technique is considered to be effective for a more secure and safer apheresis for small-to-middle-sized dogs.
In the present study, eight of the nine dogs developed hypocalcaemia during apheresis. The cause was likely the insufficient administration of calcium gluconate. The citrate contained within the anticoagulant has been utilized for apheresis; therefore, citrateinduced hypocalcaemia is well known as an apheresis-related complication. In a human study, the serum calcium concentration decreases by 33% to 39% after apheresis compared with the concentration before apheresis, and this decrease is associated with the citrate dose. 30 Therefore, a CRI of calcium gluconate solution was used to prevent citrate-induced hypocalcaemia throughout apheresis. In a previous study, the concentration of the calcium gluconate solution used in apheresis was approximately 10 times higher than that used in the present study. 18 Thus, in our study procedure, if the solution was changed to a higher concentration, a decrease in serum calcium concentration could be prevented during apheresis.
There were a few limitations in the present study: first, our sample size was small, and the fact that some differences between the groups did not reach statistical significance may have reflected a lack of power.
Second, many collected PBSCs were only evaluated in this study, and the actual ability of the apheresis product to engraft was not confirmed.
Third, we followed a single standardized apheresis protocol in this study, and fine adjustments of the machine settings such as the collection preference and ACD-A ratio were not performed to optimize the setting in each dog. The number of the PBSCs that the machine could harvest may have not been the same if the machine setting had been optimized during the apheresis according to the interim analysis of the apheresis product, as is usually carried out in clinical settings.
In conclusion, these results indicate that the apheresis procedure using Spectra Optia CMNC protocol allows safe and adequate collec- 
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